Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3056644 | Experimental Neurology | 2009 | 4 Pages |
Abstract
Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Mahendra P. Singh, Gerd Meyer zu Hörste, Wei Hu, Anne K. Mausberg, Petra D. Cravens, Todd Eagar, Stefan Löber, Ralf Klingenstein, Peter Gmeiner, Carsten Korth, Bernd C. Kieseier, Olaf Stüve,